Business Context and Reporting Period
This Form 8-K Current Report was filed by Milestone Pharmaceuticals Inc. on July 10, 2025, covering events occurring on July 10 and July 11, 2025. The company is incorporated in Québec and trades on the Nasdaq Stock Market under the symbol MIST.
Key Financial Metrics
This filing is a current report regarding specific corporate events and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Events
- Amendment to Royalty Purchase Agreement: On July 10, 2025, the Company amended its agreement with RTW Royalty I DAC. The Marketing Approval Deadline was extended from September 30, 2025, to December 31, 2025.
- Regulatory Update for CARDAMYST: On July 11, 2025, the U.S. Food and Drug Administration (FDA) accepted the Company's response to a Complete Response Letter regarding its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray. The FDA assigned a new Prescription Drug User Fee Act (PDUFA) target action date of December 13, 2025.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on future performance beyond the regulatory timeline. The primary contingency noted is the successful resolution of the FDA review process for CARDAMYST by the new PDUFA date of December 13, 2025, which aligns with the extended royalty agreement deadline.
Investor Verification Checklist
- Verify the full text of the Amendment to the Royalty Purchase Agreement with RTW Royalty I DAC, which is expected to be filed as an exhibit in the next periodic report.
- Monitor the FDA's decision on the CARDAMYST NDA by the PDUFA target date of December 13, 2025.
- Review the press release dated July 11, 2025 (Exhibit 99.1) for additional details on the FDA's acceptance of the response.